

COPY OF PAPERS  
ORIGINALLY FILED

RECEIVED

MAY 30 2002

TECH CENTER 1600/2900



I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: ASSISTANT COMMISSIONER OF PATENTS, WASHINGTON, DC 20231, ON THE DATE INDICATED BELOW.

BY: Parvula Wriggall

DATE: MAY 10, 2002

**PATENT  
BOX NON-FEE AMENDMENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re:	Patent Application of Sweeney <i>et al.</i>	: Group Art Unit: 1632
		:
		:
Appln. No.:	09/510,268	: Examiner: A. Baker
		:
Filed:	February 22, 2000	:
		: Attorney Docket
For:	THE USE OF INSULIN-LIKE GROWTH FACTOR-I IN MUSCLE	: No. 9596-61U1
		: (53893-5014)

**AMENDMENT**

This Amendment is responsive to the Communication from the Examiner dated April 23, 2002 (Paper No. 13), sent in connection with the above referenced application. In response to the Communication, please amend the application as follows.

**In the specification:**

Please amend the Brief Description of the Drawings as follows:

Beginning on page 6, line 12, and ending on page 8, line 10, please delete the section of the specification titled Brief Description of the Drawings, and replace it with the amended section set forth herein. A clean and marked-up copy of the Brief Description of the Drawings is included herein.

**BRIEF DESCRIPTION OF THE DRAWINGS**

**Figure 1A** is a diagram depicting the structure of the IGF-I rAAV construct. Rat IGF-I cDNA was placed under the control of a fast muscle-specific promoter/regulatory sequence (myosin light chain 1/3 termed "MLC 1/3") positioned at the 5' end of the IGF-I cDNA. A SV40 polyadenylation sequence (SV40pA) was positioned at the 3' end of the IGF-I cDNA. On the 3' end of the SV40pA sequence,